RESEARCH

BMC Medical Imaging

Open Access

75% radiation dose reduction using deep learning reconstruction on low-dose chest CT



Gyeong Deok Jo¹, Chulkyun Ahn^{2,3}, Jung Hee Hong⁴, Da Som Kim⁵, Jongsoo Park⁶, Hyungjin Kim¹, Jong Hyo Kim^{1,2,3}, Jin Mo Goo^{1,7*} and Ju Gang Nam^{1*}

Abstract

Objective Few studies have explored the clinical feasibility of using deep-learning reconstruction to reduce the radiation dose of CT. We aimed to compare the image quality and lung nodule detectability between chest CT using a quarter of the low dose (QLD) reconstructed with vendor-agnostic deep-learning image reconstruction (DLIR) and conventional low-dose (LD) CT reconstructed with iterative reconstruction (IR).

Materials and methods We retrospectively collected 100 patients (median age, 61 years [IQR, 53–70 years]) who received LDCT using a dual-source scanner, where total radiation was split into a 1:3 ratio. QLD CT was generated using a quarter dose and reconstructed with DLIR (QLD-DLIR), while LDCT images were generated using a full dose and reconstructed with IR (LD-IR). Three thoracic radiologists reviewed subjective noise, spatial resolution, and overall image quality, and image noise was measured in five areas. The radiologists were also asked to detect all Lung-RADS category 3 or 4 nodules, and their performance was evaluated using area under the jackknife free-response receiver operating characteristic curve (AUFROC).

Results The median effective dose was 0.16 (IQR, 0.14–0.18) mSv for QLD CT and 0.65 (IQR, 0.57–0.71) mSv for LDCT. The radiologists' evaluations showed no significant differences in subjective noise (QLD-DLIR vs. LD-IR, lung-window setting; 3.23 ± 0.19 vs. 3.27 ± 0.22 ; P = .11), spatial resolution (3.14 ± 0.28 vs. 3.16 ± 0.27 ; P = .12), and overall image quality (3.14 ± 0.21 vs. 3.17 ± 0.17 ; P = .15). QLD-DLIR demonstrated lower measured noise than LD-IR in most areas (P < .001 for all). No significant difference was found between QLD-DLIR and LD-IR for the sensitivity (76.4% vs. 72.2%; P = .35) or the AUFROCs (0.77 vs. 0.78; P = .68) in detecting Lung-RADS category 3 or 4 nodules. Under a noninferiority limit of -0.1, QLD-DLIR showed noninferior detection performance (95% CI for AUFROC difference, -0.04 to 0.06).

Conclusion QLD-DLIR images showed comparable image quality and noninferior nodule detectability relative to LD-IR images.

Keywords Artificial intelligence, Deep-learning image reconstruction, Noise reduction, Low-dose chest CT, Nodule detection

*Correspondence: Jin Mo Goo jmgoo@snu.ac.kr Ju Gang Nam dyuing89@gmail.com

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Low-dose chest CT (LDCT) is widely used for the diagnosis and follow-up of various lung diseases. Specifically, lung cancer screening using LDCT has been confirmed to reduce lung cancer mortality in several large-scale, randomized trials [1-3]; therefore, increasing number of nations are implementing lung cancer screening programs and recommending annual LDCT screening for high-risk asymptomatic individuals [4–6]. However, the cumulative radiation dose could be a major concern given the increasing number of LDCT examinations. With the technical advances achieved by CT vendors and improvements in reconstruction techniques, the radiation dose required for acquiring reliable chest CT images has steadily decreased. In particular, iterative reconstruction (IR), which substantially reduces image noise by sequentially adjusting the estimated reconstructions and the measured projections, has become a standard reconstruction technique for most CT vendors [7, 8].

Deep learning has been widely applied for various indications of medical imaging, including lesion detection, classification, segmentation, and noise reduction [9–11]. Several deep learning-based noise reduction algorithms have been proposed and tested in LDCT, and these algorithms have been reported to reduce noise and improve image quality substantially [12, 13]. Jiang et al. recently reported that lung nodule detection performance on ultralow-dose chest CT improved when using deep-learning reconstruction compared with IR [14]. However, insufficient evidence exists regarding whether deep-learning reconstruction may reproduce image quality and lesion detectability using images acquired with a decreased radiation dose. In this study, we aimed to evaluate the image quality and lung nodule detectability of CT images generated using a quarter of the low dose (QLD) and reconstructed with a commercial vendoragnostic deep-learning image reconstruction (DLIR) in comparison with those of standard LDCT images reconstructed with a dedicated IR algorithm.

Materials and methods

Patients and LDCT

Data from patients who underwent LDCT using a dualsource scanner (SOMATOM Force; Siemens Healthineers) between August 2018 and September 2018 were retrospectively collected at a tertiary care center (Seoul National University Hospital). All CT images were reviewed by a radiology resident (G.D.J. with 4 years of experience in chest CT interpretation). The patients were collected consecutively, while patients with more than five nodules, acute lung disease including pneumonia or pneumothorax, or severe architectural distortion were excluded to focus more clearly on the aims of the present study (Fig. 1). Demographic information (age, sex) and CT radiation dose information (CTDI_{vol}, DLP, and effective dose) were documented. All CT images were reviewed and the presence of a lung nodule was determined consensually by a thoracic radiologist (J.G.N. with 9 years of experience) and a radiology resident (G.D.J.). The size of all nodules was calculated as the average of the maximal long-axis and the maximal perpendicular short-axis measurements.

CT Acquisition and Image Reconstruction

For all LDCT scans, radiation was provided using two generators, whose radiation dose was split into a 1:3 ratio. QLD CT images were generated using the data acquired from a single generator, which provided a quarter dose of radiation, while standard-dose LDCT images were generated using the combined data from two generators. For each scan, the CT parameters were set as follows: tube voltage, 120 kVp; automatic tube current modulation by Care Dose 4D system (Siemens Healthineers) with quality reference tube-current-time product (15 mAs for one tube and 5 mAs for the other tube) and target CTDI_{vol} (1.36 mGy); detector collimation, 0.6 mm; detector pitch, 1.15; and gantry rotation period, 285 ms. The median scan range was 41.1 (IQR, 38.6–42.6) cm. Contrast media was not used.

For image reconstruction, advanced modeled iterative reconstruction (ADMIRE, level 3) was applied to standard-dose LDCT images (hereafter, LD-IR images) [7], and deep-learning image reconstruction (high level for soft-kernel reconstruction, intermediate level for sharpkernel reconstruction) was applied to QLD CT images (hereafter, QLD-DLIR images). Representative images are shown in Figs. 2, 3 and 4.

Deep-learning image reconstruction

We used a commercial, vendor-agnostic deep-learning image reconstruction software (DLIR; ClariCT.AI, ClariPI Inc.), which has received European (CE Mark) and Korean regulatory approval (Korean Food and Drug Administration) [15]. This software takes filtered back-projection images as input and generates denoised images, and users can manipulate the optimal denoising level. This software is applicable to any type of filtered back projection images regardless of CT vendor, scan protocol, reconstruction kernel, and section thickness. A detailed description of the software is provided in Appendix E1 (online).

Quantitative and qualitative image quality assessment

Image noise and the signal-to-noise ratio (SNR) were measured by a radiology resident (G.D.J.) in five different locations, including the lung parenchyma, trachea, aorta, muscle, and axillary fat (Figure E1). Image noise was defined as the standard deviation of the HU values within



Fig. 1 Patient selection flow diagram

a region of interest larger than 0.5 cm², while the signalto-noise ratio was calculated as the absolute average HU value divided by the noise. To assess the spatial resolution, the edge-rise-distance (ERD) was measured semiautomatically at pulmonary vessels running in the axial plane. The ERD was defined as the distance between two points yielding 10% and 90% of the maximal intravascular HU values [12, 16]. All quantitative measures were evaluated for both 3-mm section-thickness standard-kernel images and 1-mm section-thickness sharp-kernel images.

For a qualitative assessment, three fellowship-trained thoracic radiologists (J.H.H., D.S.K., J. P. with 8–10 years of experience) evaluated the image quality of 200 randomly arranged image sets (QLD-DLIR and LD-IR) from 100 patients. Each radiologist assessed all 200 sets of images and these images were randomly distributed, ensuring that pairs of QLD-DLIR and LD-IR images from the same patient were not presented together. The radiologists independently reviewed subjective noise, spatial resolution, the presence of artifacts (distortion and beam-hardening artifacts), and overall image quality using a 4-point scale (1–4; a higher score indicated better image quality, Table E1 [online]). A distortion artifact was defined as the presence of image distortion generated from image reconstruction algorithms, typically false miliary nodules on the lung-window setting and granular distortion of mediastinal structures [12]. The primary evaluation was conducted using 3-mm section-thickness standard-kernel images, and 1-mm section-thickness sharp-kernel images were provided as a pair. The radiologists were blinded to patients' demographics, clinical indications, and the reconstruction technique of the images. Inter-reader agreement was assessed using the intraclass correlation coefficient (ICC) based on a two-way mixed-effect model incorporating consistency and average measures. The agreement levels were categorized as follows: poor (<0.50), fair (0.50–0.75), good (0.75–0.90), and excellent (0.90–1.00).

Lung nodule detectability assessment

For nodule detectability, a performance test was conducted using the same 200 randomly arranged image sets used in the qualitative assessment. The three aforementioned fellowship-trained thoracic radiologists detected and localized all clinically significant nodules (solid or part-solid nodules ≥ 6 mm; Lung-RADS category 3 or 4) [17]. The radiologists rated their confidence in lesion detection using a 5-point scale, where a higher score indicated higher confidence in the presence of a Lung-RADS category 3 or 4 nodule [18]. For evaluation, 3-mm



Fig. 2 A woman received low-dose chest CT for the follow-up evaluation of a previously detected 8-mm ground-glass nodule in the left upper lobe. (A-C) Conventional low-dose chest CT images were reconstructed with iterative reconstruction, and (D-F) the images generated using a quarter dose of radiation were reconstructed with commercial deep-learning software. (A, D) Soft-tissue structures, including the aorta, subcutaneous fat, and paraspinal muscles, were visualized with a lower noise level in the mediastinal-window setting. (C, F) A ground-glass nodule in the left upper lobe was well visualized with a sharp margin on both images (arrow)

section-thickness standard-kernel images were provided as main images, and 1-mm section-thickness sharp-kernel images were provided as a pair for the further evaluation of nodule morphology (i.e., solid or subsolid) and to make accurate measurements. The radiologists were blinded to patients' demographics, clinical indications, and the reconstruction technique of the images.

Statistical analysis

Image quality metrics from QLD-DLIR and LD-IR were compared using the Wilcoxon signed-rank test or paired *t*-test, as appropriate. To assess lung nodule detectability, area under the jackknife free-response receiver operating characteristic curves (AUFROCs) were evaluated and compared between QLD-DLIR and LD-IR images, and the noninferiority limit was established as -0.1 [19, 20]. Sensitivity and specificity were compared using the McNemar test for individual radiologists and generalized estimating equations based on an exchangeable correlation matrix for the pooled radiologists. AUFROC analysis was performed using JAFROC version 4.2.1 and ICC was calculated using MedCalc version 20.218 (MedCalc software, Mariakerke, Belgium), while other statistical analyses were performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). The statistical analyses were conducted by two radiologists (G.D.J. and J.G.N.) with 4 and 9 years of experience in medical statistical analyses. For all tests, P < .05 indicated statistical significance.

Results

Patient characteristics, clinical indications, nodule types, and radiation exposure

This study included 100 patients [median (IQR), 61 (53-70) years] including 52 men and 48 women (Table 1). LDCT was mostly indicated for the evaluation of thoracic metastasis (follow-up or initial workup; n=57) or the follow-up of underlying thoracic diseases (n=33; including lung nodules [n=22], emphysema [n=3], and others [n=8]). Ten other patients received chest CT for a preoperative/pretransplantation workup (n=2), further evaluation of abnormalities found on chest radiography (n=7), or chronic cough (n=1). Among the 100 patients, 30 had at least one clinically significant nodule (Lung-RADS category 3 or 4). In total, 48 Lung-RADS category 3 (n=28)or 4 (n=20) nodules were present; four were subsolid nodules and 44 were solid nodules. The median CTDI_{vol} and DLP were 0.29 (IQR, 0.25-0.32) mGy and 11.6 (IQR, 10.2-12.7) mGy*cm for QLD CT and 1.2 (IQR, 1.0-1.3) mGy and 46.4 (IQR, 41.0-50.8) mGy*cm for LDCT, respectively. The median effective dose was 0.16 (IQR, 0.14-0.18) mSv for QLD CT and 0.65 (IQR, 0.57-0.71) mSv for LDCT.



Fig. 3 A woman received low-dose chest CT for the follow-up evaluation of multiple ground-glass nodules. (A-C) Conventional low-dose chest CT images were reconstructed with iterative reconstruction, and (D-F) the images generated using a quarter dose of radiation were reconstructed with commercial deep-learning software. (A, D) Soft-tissue structures, including the liver, spleen, kidney, and paraspinal muscles, were visualized with a lower noise level in the mediastinal-window setting on both images. (C, F) A ground-glass nodule in the right upper lobe was well visualized with a sharp margin on both images (arrow)



Fig. 4 A man received low-dose chest CT for the follow-up evaluation of a spiculated lung nodule. (A-C) Conventional low-dose chest CT images were reconstructed with iterative reconstruction, and (D-F) the images generated using a quarter dose of radiation were reconstructed with commercial deep-learning software. (A, D) Soft-tissue structures including calcified mediastinal lymph nodes were visualized with a lower noise level in the mediastinal-window setting on both images. (C, F) A spiculated nodule in the left upper lobe was well visualized with a sharp margin on both images (arrow)

Table 1	Patient Characteristics and Radiologic Finding	qs

Demographics 61 [53–70] Sex 52 (52%) Men 52 (52%) Women 48 (48%) CT information 57 (57%) Indication for CT 57 (57%) Metastasis evaluation 57 (57%) Follow-up of underlying diseases 33 (33%) Preoperative/pretransplantation workup 2 (2%) Chest radiograph abnormality 7 (7%) Chronic cough 1 (1%) CTDI _{vol} (mGy; median [IQR]) 1 LDCT 12 [1.0–1.3] QLD CT QLD CT 2.29 DLP (mGy*cm; median [IQR]) 1.2 LDCT 1.6 [0.12–127] 28 Effective dose (mSv; median [IQR]) 1.6 LDCT 0.65 [0.57–0.71] 2.57–0.71] QLD CT 0.16 [0.14–0.18] 30 (30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4 A 16 (33%) Lung-RADS category 4 A 16 (33%) Lung-RADS category 4 B 4(8%)	Variable	Number
Age (median [IQR])61 [53–70]Sex52 (52%)Women48 (48%)CT information48 (48%)CT information57 (57%)Indication for CT57 (57%)Metastasis evaluation57 (57%)Follow-up of underlying diseases33 (33%)Preoperative/pretransplantation workup2 (2%)Chest radiograph abnormality7 (7%)Chronic cough1 (1%)CTDI _{vol} (mGy; median [IQR])12LDCT12[1.0–1.3]2)2QLD CT0.29[0.25–0.32]2)2DLP (mGy*cm; median [IQR])11.6LDCT46.4[1.0–50.8]2)2QLD CT1.6[0.27–0.71]21.6QLD CT0.65[0.57–0.71]0.16QLD CT0.16[0.14–0.18]30 (30%)Number of lung nodules48Lung-RADS category 3 or 4 nodules30 (30%)Number of lung nodules48Lung-RADS category 4 A16 (33%)Lung-RADS category 4 B4 (8%)Subsolid4 (8%)Subsolid4 (8%)	Demographics	
Sex Men 52 (52%) Women 48 (48%) CT information 1 Indication for CT 57 (57%) Metastasis evaluation 57 (57%) Follow-up of underlying diseases 33 (33%) Preoperative/pretransplantation workup 2 (2%) Chest radiograph abnormality 7 (7%) Chronic cough 1 (1%) CTDI _{vol} (mGy; median [IQR]) 12 LDCT 12 QLD CT 0.29 [0.25-0.32] 0LP (mGy*cm; median [IQR]) LDCT 46.4 [1.0-1.3] 2LD CT QLD CT 1.6 [1.0-2.12.7] 2Ffective dose (mSv; median [IQR]) LDCT 6.5 QLD CT 0.65 [0.57-0.71] 2[0.57-0.71] QLD CT 0.16 [0.14-0.18] 23 (30%) Number of lung nodules 48 Lung-RADS category 3 24 (58%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Subsolid 4 (8%)	Age (median [IQR])	61 [53–70]
Men 52 (52%) Women 48 (48%) CT information Indication for CT Metastasis evaluation 57 (57%) Follow-up of underlying diseases 33 (33%) Preoperative/pretransplantation workup 2 (2%) Chest radiograph abnormality 7 (7%) Chronic cough 1 (1%) CTDl _{vol} (mGy; median [IQR]) 1 LDCT 1.2 QLD CT 0.29 DLP (mGy*cm; median [IQR]) 1.2 DLP (mGy*cm; median [IQR]) 1.6 QLD CT 1.6 QLD CT 0.65 [0.57-0.71] 1.6 QLD CT 0.65 QLD CT 0.65 [0.57-0.71] 1.6 QLD CT 1.6 QLD CT 0.65 [0.57-0.71] 1.6 [0.14-0.18] 0.30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4 A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4(8%) Subsolid<	Sex	
Women 48 (48%) CT information Indication for CT Metastasis evaluation 57 (57%) Follow-up of underlying diseases 33 (33%) Preoperative/pretransplantation workup 2 (2%) Chest radiograph abnormality 7 (7%) Chronic cough 1/2 CTDI _{vol} (mGy; median [IQR]) I LDCT 1.2 QLD CT 0.29 DLP (mGy*cm; median [IQR]) I LDCT 46.4 [41.0–50.8] 202–10.2] DLP (mGy*cm; median [IQR]) I LDCT 1.6 QLD CT 0.65 [0.57–0.71] 1.6 [0.57–0.71] 0.16 QLD CT 0.16 DLP 1.16 [0.57–0.71] 0.16 QLD CT 0.65 [0.57–0.71] 0.16 QLD CT 0.16 DLT 0.16 QLD CT 0.16 QLD CT 0.16 QLD CT 0.16 <t< td=""><td>Men</td><td>52 (52%)</td></t<>	Men	52 (52%)
CT information Indication for CT Metastasis evaluation 57 (57%) Follow-up of underlying diseases 33 (33%) Preoperative/pretransplantation workup 2 (2%) Chest radiograph abnormality 7 (7%) Chronic cough 1 (1%) CTDl _{vol} (mGy; median [IQR]) 1 LDCT 1.2 QLD CT 0.29 DLP (mGy*cm; median [IQR]) 1025-0.32] DLP (mGy*cm; median [IQR]) 1.6 LDCT 46.4 [41.0-50.8] 0.29 QLD CT 0.65 [0.27-0.71] 0.65 QLD CT 0.65 [0.57-0.71] 0.16 QLD CT 0.65 [0.57-0.71] 0.16 QLD CT 0.16 [0.14-0.18] 10.30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4 A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4 (8%) Subsolid 4 (8%)	Women	48 (48%)
Indication for CT 57 (57%) Metastasis evaluation 57 (57%) Follow-up of underlying diseases 33 (33%) Preoperative/pretransplantation workup 2 (2%) Chest radiograph abnormality 7 (7%) Choronic cough 1 (1%) CTDI _{vol} (mGy; median [IQR]) 1 LDCT 1.2 QLD CT 0.29 DLP (mGy*cm; median [IQR]) 1 LDCT 46.4 [41.0–50.8] QLD CT 1.6 [10.2–12.7] 11.6 [10.2–12.7] 1.6 Preoperative dose (mSv; median [IQR]) 1 LDCT 46.4 [41.0–50.8] [0.57–0.71] QLD CT 0.65 [0.57–0.71] [0.57–0.71] QLD CT 0.16 [0.14–0.18] 30 (30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4 (8%) Subsolid 4 (8%)	CT information	
Metastasis evaluation57 (57%)Follow-up of underlying diseases33 (33%)Preoperative/pretransplantation workup2 (2%)Chest radiograph abnormality7 (7%)Chronic cough1 (1%)CTDI _{vol} (mGy; median [IQR])1 (1%)LDCT1.2 [1.0–1.3]QLD CT0.29 [0.25–0.32]DLP (mGy*cm; median [IQR])11.6 [1.0–1.3]QLD CT46.4 [41.0–50.8]QLD CT1.6 [0.2–12.7]Effective dose (mSv; median [IQR])11.6 [0.2–12.7]LDCT0.65 [0.57–0.71]QLD CT1.6 [0.37–0.71]QLD CT1.6 [0.37–0.71]QLD CT1.6 [0.37–0.71]QLD CT1.6 [0.3%)Mumber of lung nodules48Lung-RADS category 328 (58%)Lung-RADS category 4A16 (33%)Lung-RADS category 4B Radiologic nodule type4 (8%)Solid44 (92%)	Indication for CT	
Follow-up of underlying diseases33 (33%)Preoperative/pretransplantation workup2 (2%)Chest radiograph abnormality7 (7%)Chronic cough1 (1%)CTDI _{vol} (mGy; median [IQR])1 (1%)LDCT1.2 [1.0-1.3]QLD CT0.29 [0.25-0.32]DLP (mGy*cm; median [IQR])11.6 [10.2-1.2.7]LDCT46.4 [41.0-50.8]QLD CT11.6 [10.2-12.7]Effective dose (mSv; median [IQR])11.6 [0.57-0.71]LDCT0.65 [0.57-0.71]QLD CT0.16 [0.14-0.18]Patients with Lung-RADS category 3 or 4 nodules30 (30%)Number of lung nodules48Lung-RADS category 416 (33%)Lung-RADS category 4B4 (8%)Radiologic nodule type4 (8%)Solid44 (92%)	Metastasis evaluation	57 (57%)
Preoperative/pretransplantation workup2 (2%)Chest radiograph abnormality7 (7%)Chronic cough1 (1%)CTDI _{vol} (mGy; median [IQR])1LDCT1.2 [1.0–1.3]QLD CT0.29 [0.25–0.32]DLP (mGy*cm; median [IQR])11.6 [41.0–50.8]QLD CT46.4 [41.0–50.8]QLD CT11.6 [10.2–12.7]Effective dose (mSv; median [IQR])0.65 [0.57–0.71]LDCT0.65 [0.57–0.71]QLD CT11.6 [10.4–0.18]Patients with Lung-RADS category 3 or 4 nodules30 (30%)Number of lung nodules48 [48]Lung-RADS category 4A16 (33%) [20]Lung-RADS category 4B4 (8%)Radiologic nodule type4Subsolid44 (92%)	Follow-up of underlying diseases	33 (33%)
Chest radiograph abnormality 7 (7%) Chronic cough 1 (1%) CTDI _{vol} (mGy; median [IQR]) 1.2 LDCT 1.2 QLD CT 0.29 DLP (mGy*cm; median [IQR]) 1.2 LDCT 46.4 [41.0–50.3] QLD CT 11.6 [0.27–0.32] 11.6 DLP (mGy*cm; median [IQR]) 11.6 LDCT 46.4 [1.0–1.3] 21.2 QLD CT 11.6 [1.0–1.3] 21.2 Effective dose (mSv; median [IQR]) 11.6 LDCT 0.65 [0.57–0.71] 21.6 QLD CT 0.16 [0.14–0.18] 21.4 Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 4 28 (58%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4 (8%) Solid 44 (92%)	Preoperative/pretransplantation workup	2 (2%)
Chronic cough 1 (1%) CTDI _{vol} (mGy; median [IQR]) 1.2 LDCT [1.0-1.3] QLD CT 0.29 DLP (mGy*cm; median [IQR]) 1000000000000000000000000000000000000	Chest radiograph abnormality	7 (7%)
CTDI _{vol} (mGy; median [IQR]) 1.2 LDCT 1.0–1.3] QLD CT 0.29 DLP (mGy*cm; median [IQR]) [1.0–1.3] LDCT 46.4 QLD CT [1.0–1.3] QLD CT [1.0–1.3] QLD CT [1.0–1.3] QLD CT [1.0–1.3] QLD CT 11.6 [10.2–12.7] [10.2–12.7] Effective dose (mSv; median [IQR]) I LDCT 0.65 [0.57–0.71] [0.14–0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 4 48(%) Lung-RADS category 4 4(8%) Lung-RADS category 4 4(8%) Radiologic nodule type 4(8%) Subsolid 4(8%)	Chronic cough	1 (1%)
LDCT 1.2 QLD CT 0.29 DLP (mGy*cm; median [IQR]) [0.25-0.32] DLP (mGy*cm; median [IQR]) [41.0-50.8] QLD CT 1.6 [10.2-12.7] [10.2-12.7] Effective dose (mSv; median [IQR]) [0.27-0.71] LDCT 0.65 [0.14-0.18] [0.14-0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 4 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4 (8%) Solid 44 (92%)	CTDI _{vol} (mGy; median [IQR])	
QLD CT [1.0–1.3] QLD CT 0.29 [0.25–0.32] DLP (mGy*cm; median [IQR]) LDCT 46.4 [41.0–50.8] [41.0–50.8] QLD CT 11.6 [10.2–12.7] Effective dose (mSv; median [IQR]) LDCT 0.65 QLD CT 0.65 [0.27–0.71] [0.14–0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 4 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4 (8%) Subsolid 44 (92%)	LDCT	1.2
QLD CT 0.29 [0.25-0.32] DLP (mGy*cm; median [IQR]) LDCT 46.4 [41.0-50.8] [41.0-50.8] QLD CT 11.6 [10.2-12.7] Effective dose (mSv; median [IQR]) LDCT 0.65 [0.57-0.71] 0.16 [0.14-0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 4 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4 (8%) Subsolid 44 (92%)		[1.0–1.3]
[0.25–0.32] DLP (mGy*cm; median [IQR]) LDCT 46.4 [41.0–50.8] QLD CT 11.6 [10.2–12.7] Effective dose (mSv; median [IQR]) LDCT 0.65 [0.57–0.71] QLD CT 0.16 [0.14–0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 3 Lung-RADS category 4A Lung-RADS category 4B Adiologic nodule type Subsolid 4 (8%) Solid 44 (92%)	QLD CT	0.29
DLP (mGy*cm; median [IQR]) LDCT 46.4 [41.0–50.8] QLD CT 11.6 [10.2–12.7] Effective dose (mSv; median [IQR]) LDCT 0.65 [0.57–0.71] QLD CT 0.16 [0.14–0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 4 16 (33%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 50lid 4 (8%)		[0.25–0.32]
LDCT 46.4 [41.0-50.8] QLD CT 11.6 [10.2-12.7] Effective dose (mSv; median [IQR]) LDCT 0.65 [0.57-0.71] QLD CT 0.16 [0.14-0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 50lid 44 (92%)	DLP (mGy*cm; median [IQR])	
QLD CT [1,0=50.8] Effective dose (mSv; median [IQR]) [10,2=12.7] Effective dose (mSv; median [IQR]) 0.65 LDCT 0.65 [0,57=0.71] 0.16 [0,14=0.18] 30 (30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type Subsolid 4 (8%)	LDCT	46.4
QLD C1 11.6 [10.2–12.7] Effective dose (mSv; median [IQR]) LDCT 0.65 [0.57–0.71] QLD CT 0.16 [0.14–0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4(8%) Radiologic nodule type 5 Subsolid 44 (92%)		[41.0-50.8]
Effective dose (mSv; median [IQR]) LDCT 0.65 QLD CT 0.16 Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type Subsolid 4 (8%)	QLD CT	11.0 [10.2_12.7]
LDCT 0.65 [0.57-0.71] 0.16 [0.14-0.18] 0.30%) Number of lung nodules 48 Lung-RADS category 3 or 4 nodules 48 Lung-RADS category 4 16 (33%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 5 Subsolid 44 (92%)	Effective dose (mSv: median [IOB])	[10.2 12.7]
DLD CT [0.57-0.71] QLD CT 0.16 [0.14-0.18] Patients with Lung-RADS category 3 or 4 nodules 30 (30%) Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 50lid Subsolid 44 (92%)		0.65
QLD CT0.16 [0.14-0.18]Patients with Lung-RADS category 3 or 4 nodules30 (30%)Number of lung nodules48Lung-RADS category 328 (58%)Lung-RADS category 4 A16 (33%)Lung-RADS category 4B4 (8%)Radiologic nodule type50lidSubsolid4 (8%)		[0.57-0.71]
[0.14-0.18]Patients with Lung-RADS category 3 or 4 nodules30 (30%)Number of lung nodules48Lung-RADS category 328 (58%)Lung-RADS category 4 A16 (33%)Lung-RADS category 4B4 (8%)Radiologic nodule type50 idSubsolid44 (92%)	QLD CT	0.16
Patients with Lung-RADS category 3 or 4 nodules30 (30%)Number of lung nodules48Lung-RADS category 328 (58%)Lung-RADS category 4 A16 (33%)Lung-RADS category 4B4 (8%)Radiologic nodule type50 didSubsolid44 (92%)		[0.14-0.18]
Number of lung nodules 48 Lung-RADS category 3 28 (58%) Lung-RADS category 4 A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4 (8%) Subsolid 44 (92%)	Patients with Lung-RADS category 3 or 4 nodules	30 (30%)
Lung-RADS category 3 28 (58%) Lung-RADS category 4 A 16 (33%) Lung-RADS category 4B 4 (8%) Radiologic nodule type 4 (8%) Subsolid 4 (8%) Solid 44 (92%)	Number of lung nodules	48
Lung-RADS category 4 A16 (33%)Lung-RADS category 4B4 (8%)Radiologic nodule type4 (8%)Subsolid4 (8%)Solid44 (92%)	Lung-RADS category 3	28 (58%)
Lung-RADS category 4B4 (8%)Radiologic nodule type4Subsolid4 (8%)Solid44 (92%)	Lung-RADS category 4 A	16 (33%)
Radiologic nodule typeSubsolid4 (8%)Solid44 (92%)	Lung-RADS category 4B	4 (8%)
Subsolid 4 (8%) Solid 44 (92%)	Radiologic nodule type	
Solid 44 (92%)	Subsolid	4 (8%)
	Solid	44 (92%)

Note.—Categorical variables are presented as counts (%) and continuous variables as median [IQR].

 ${\sf CTDI}_{vol}{=}{\sf volume}\ {\sf CT}\ dose\ index,\ {\sf LDCT}{=}{\sf low}{-}dose\ {\sf CT},\ {\sf IQR}{=}{\sf interquartile}\ range,\ {\sf Lung}{-}{\sf RADS}{=}{\sf lung}\ imaging\ reporting\ and\ data\ system,\ {\sf QLD}{=}\ quarter\ of\ the\ low\ dose.$

Quantitative image quality assessment

The QLD-DLIR images showed lower noise and higher SNR than the LD-IR images in most evaluated areas (P<.001), except for trachea in 3-mm, standard-kernel images, for which the QLD-DLIR images showed higher noise (16.0±3.9 vs. 13.4±2.0; P<.001) and a lower SNR (64.3±14.6 vs. 75.8±11.7; P<.001) than the LD-IR images (Table 2). The ERD of the QLD-DLIR images was lower than that of the LD-IR images (1.52±0.08 vs. 1.80±0.11; P<.001) in 3-mm, standard-kernel images, indicating the superior spatial resolution of QLD-DLIR images. In 1-mm, sharp-kernel images, however, the ERD of QLD-DLIR images was higher than that of LD-IR images (1.15±0.07 vs. 1.06±0.08; P<.001).

Qualitative image Quality Assessment

For 3-mm, standard-kernel images, the QLD-DLIR and LD-IR images did not show significant differences in overall image quality (QLD-DLIR vs. LD-IR; 3.14±0.21 vs. 3.17 \pm 0.17; P=.15). Specifically, the QLD-DLIR and LD-IR images showed similar quality in terms of subjective noise (QLD-DLIR vs. LD-IR; 3.23±0.19 vs. 3.27 ± 0.22 ; P=.11), spatial resolution (3.14 ± 0.28 vs. 3.16 ± 0.27 ; P = .12), and distortion artifacts (3.08 ± 0.24 vs. 3.07 ± 0.19 ; P=.78; Table 3) in the lung-window setting; however, the QLD-DLIR images showed lower scores for subjective noise, spatial resolution, and distortion artifacts in the mediastinal-window setting, as well as the presence of beam-hardening artifacts (Table 3, Figure E2). For 1-mm, sharp-kernel images, the QLD-DLIR images showed lower image quality in all aspects, including overall image quality, when compared with LD-IR images (Table E2). The radiologists showed poor interreader agreement in assessing subjective noise (lung window setting) and presence of distortion artifact (Table 3).

Nodule detectability assessment

Among the CT scans of the 100 included patients, 48 Lung-RADS category 3 (n=28) or 4 (n=20) nodules (4 subsolid and 44 solid nodules) were found in 30 patients, and those nodules were regarded as positive nodules, while Lung-RADS category 2 nodules were regarded as negative. In patient-based analyses, all three thoracic radiologists showed similar sensitivity and specificity values when using QLD-DLIR and LD-IR images (P>.05 for all, Table E3). The pooled radiologists showed sensitivity values of 78.9% (71/90) and 81.1% (73/90, P=.45) using QLD-DLIR and LD-IR images, respectively, and specificity values of 83.3% (175/210) and 84.3% (177/210; *P*=.74). On nodule-based analyses, all three thoracic radiologists showed similar nodule-based sensitivity (number of detected true-positive nodules divided by the total number of positive nodules) and false-positive rates (number of false-positive nodules divided by the total number of patients) using QLD-DLIR and LD-IR images (P>.05 for all; Table 4). In the pooled analysis, the nodule-based sensitivity values were 76.4% (110/144) and 72.2% (104/144; P=.35) when using QLD-DLIR and LD-IR, respectively, while the false-positive rates were 0.34 (102/300) and 0.34 (102/300; *P*=1.00), each. In the JAFROC analysis, all three thoracic radiologists showed similar AUFROCs in detecting Lung-RADS 3 or 4 nodules using QLD-DLIR and LD-IR images (0.72 vs. 0.75. P=.38; 0.86 vs. 0.82, P=.36; and 0.72 vs. 0.75, P=.52). The pooled AUFROC also did not show a significant difference (0.77 vs. 0.78; P=.68) between the QLD-DLIR and LD-IR images. With a noninferiority limit of -0.1, the three thoracic radiologists showed noninferior detection performance using QLD-DLIR instead of LD-IR (95% CI for AUFROC

	QLD-DLIR,	LD-IR	P-value*	QLD-DLIR	LD-IR	P-val-	
	(3-mm thickness,	(3-mm thickness,		(1-mm thickness,	(1-mm thickness,	ue*	
	standard kernel)	standard kernel)		sharp kernel)	sharp kernel)		
Noise							
Lung	11.5 ± 3.3	16.0 ± 3.8	< 0.001	37.1±6.7	66.5 ± 10.9	< 0.001	
Trachea	16.0 ± 3.9	13.4 ± 2.0	< 0.001	44.2 ± 7.7	57.5 ± 8.4	< 0.001	
Aorta	8.6±2.3	17.6±2.2	< 0.001	81.8±6.1	104.9±7.2	< 0.001	
Muscle	12.2±3.3	22.8 ± 3.3	< 0.001	81.0±9.5	111.8±9.9	< 0.001	
Axillary fat	9.2±2.0	17.4±3.3	< 0.001	82.1±11.6	108.3 ± 16.6	< 0.001	
SNR							
Lung	84.4±24.3	58.9 ± 14.1	< 0.001	23.0 ± 4.6	13.7±2.5	< 0.001	
Trachea	64.3±14.6	75.8±11.7	< 0.001	20.1 ± 3.6	16.6±2.7	< 0.001	
Aorta	5.6 ± 1.3	2.6 ± 0.4	< 0.001	0.58 ± 0.06	0.43 ± 0.06	< 0.001	
Muscle	5.0 ± 1.4	2.5 ± 0.5	< 0.001	0.71±0.12	0.49 ± 0.08	< 0.001	
Axillary fat	11.3 ± 2.8	6.0 ± 1.2	< 0.001	1.2±0.2	0.95 ± 0.16	< 0.001	
Edge-rise-distance (mm)	1.52±0.08	1.80 ± 0.11	< 0.001	1.15 ± 0.07	1.06 ± 0.08	< 0.001	

Table 2 Quantitative Image Quality Assessment Results

Note.—Data are presented as means±standard deviations. Italicized data indicate that the values are lower (for noise and edge-rise-distance) or higher (for SNR) than the compared counterpart. DLIR=deep-learning image reconstruction, IR=iterative reconstruction, LD=low dose, QLD=quarter of the low dose, SNR=signal-to-noise ratio

*P-values were calculated using the paired t-test

Table 3 Qualitative Image Quality Assessment Results

	QLD-DLIR	LD-IR	P-value*	ICC [95% CI]
Lung-window setting				
Subjective noise	3.23±0.19 (3, 3.33)	3.27±0.22 (3, 3.33)	0.11	0.26 [0.12, 0.38]
Spatial resolution	3.14±0.28 (3, 3.33)	3.16±0.27 (3, 3.33)	0.12	0.51 [0.42, 0.59]
Distortion artifact	3.08±0.24 (3, 3.33)	3.07±0.19 (3, 3)	0.78	0.52 [0.43, 0.60]
Mediastinal-win- dow setting				
Subjective noise	3.00±0.19 (3, 3)	3.05±0.14 (3, 3)	0.045	0.88 [0.85, 0.87]
Spatial resolution	2.92±0.29 (2.67, 3)	3.22±0.29 (3, 3.33)	< 0.001	0.39 [0.28, 0.49]
Distortion artifact	2.75±0.18 (2.67, 2.92)	3.04±0.14 (3, 3)	< 0.001	-0.34 [-0.58, -0.13]
Beam-hardening artifact	3.01 ± 0.35 (2.75, 3.33)	3.47±0.27 (3.33, 3.67)	< 0.001	0.64 [0.57, 0.69]
Overall image quality	3.14±0.21 (3, 3.33)	3.17±0.17 (3, 3.33)	0.15	0.45 [0.35, 0.54]

Note.—Results from 3-mm, standard-kernel images are presented. Data are presented as means±standard deviations (interquartile range). Higher scores indicate better image quality. Italicized data indicate that the values are higher than the compared counterpart. Cl=confidence interval, DLIR=deep-learning image reconstruction, ICC=intraclass correlation coefficient, IR=iterative reconstruction, LD=low dose, QLD=quarter of the low dose

* $^{p}\mbox{-}values$ were calculated using the paired $t\mbox{-}test$ or Wilcoxon signed-rank test, as appropriate

difference; -0.04, 0.06). Representative cases for lung nodules are provided in Figs. 2, 3 and 4 and an example of a false-negative case is provided in Figure E3.

Discussion

In this study, we compared the image quality of chest CT generated using a quarter dose of radiation and reconstructed with commercial deep-learning software (QLD-DLIR) to that of conventional LDCT images generated using full radiation dose and reconstructed with a dedicated IR technique (LD-IR). In the quantitative analysis, the QLD-DLIR images showed overall better noise, SNR, and ERD than the LD-IR images, suggesting better noise, image contrast, and spatial resolution, respectively. In the subjective, qualitative assessment, the QLD-DLIR and LD-IR images received comparable image quality scores in the lung evaluation, whereas the QLD-DLIR images showed lower spatial resolution with more noise and artifacts in the mediastinal evaluation. The three thoracic radiologists found no significant differences in overall image quality between the QLD-DLIR and LD-IR images. The detection performance of significant lung nodules was also evaluated. The radiologists did not show significantly different performance in detecting Lung-RADS 3 or 4 nodules on the QLD-DLIR and LD-IR images. The noninferiority of QLD-DLIR relative to LD-IR was confirmed.

The radiation dose required for reliable lung evaluation has substantially decreased since the introduction of IR, enabling LDCT to become the mainstream CT protocol in screening for lung diseases, including lung cancer. More recently, deep learning–based reconstruction has demonstrated excellent noise-reduction power, surpassing IR, suggesting the possibility of further radiation dose reduction [21–23]. Several studies have reported the feasibility of ultralow-dose chest CT images reconstructed with deep learning software [12, 14, 24]. However, those Table 4 Nodule-Based Estimates of the Detection of Lung-RADS Category 3 or 4 Nodules

	AUFROC			Sensitivity			FP rate		
	QLD-DLIR	LD-IR	P-value*	QLD-DLIR	LD-IR	P-value*	QLD-DLIR	LD-IR	P-value*
Reader 1	0.72 (0.62–0.82)	0.75 (0.66– 0.85)	0.38	77.1% (37/48)	72.9% (35/48)	0.73	0.29 (29/100)	0.36 (36/100)	0.29
Reader 2	0.86 (0.78–0.94)	0.82 (0.74– 0.91)	0.36	79.2% (38/48)	68.8% (33/48)	0.30	0.10 (10/100)	0.10 (10/100)	1.00
Reader 3	0.72 (0.63–0.82)	0.75 (0.66– 0.84)	0.52	72.9% (35/48)	75.0% (36/48)	1.00	0.63 (63/100)	0.56 (56/100)	0.31
Pooled readers	0.77 (0.70–0.83)	0.78 (0.71– 0.85)	0.68	76.4% (110/144)	72.2% (104/144)	0.35	0.34 (102/300)	0.34 (102/300)	1.00

Note.—AUFROC values are presented with 95% confidence intervals. FP rates were calculated as the total number of FP nodules divided by the total number of patients (n=100)

AUFROC=area under the jackknife free-response receiver operating characteristic curve, DLIR=deep-learning image reconstruction, FP=false positive, IR=iterative reconstruction, LD=low dose, Lung-RADS=lung imaging reporting and data system, QLD=quarter of the low dose

*P-values were calculated using jackknife free-response receiver operating characteristic curve analysis (for the AUFROC), the McNemar test (for the sensitivity of individual radiologists), the chi-square test (for the FP rate of individual radiologists), or generalized estimating equations (for the sensitivity and specificity of pooled radiologists)

previous publications have not yet provided concrete evidence that deep learning may actually reduce the radiation dose required for reliable lung evaluations, as deep learning—reconstructed ultralow-dose CT scans have not been compared with conventional LDCT reconstructed using conventional IR. In this study, we attempted a 75% dose reduction in LDCT using commercial deep-learning reconstruction software. By using a dual-source scanner, we obtained quarter-dose and full-dose CT images simultaneously from a single scan, without imposing additional radiation.

The commercial deep-learning software we used in this study, ClariCT.AI, has the advantage of being applicable to any CT images (vendor-agnostic) without any vendor-specific adaptations. The software was trained with multi-vendor images through the synthetic sinogrambased low-dose simulation technique [25], producing generalizable denoising quality for diverse images. It has also been reported to produce less deep learning-specific image distortion [12], possibly by preserving the noise frequency spectrum during the denoising process. We tested a single software instead of various deeplearning reconstruction models, as it was technically the only applicable commercial deep-learning denoising software for the CT images taken from our dual-source scanner; however, a further comparison with other deeplearning models using multi-vendor CT scans would be warranted.

To assess the clinical feasibility of the images, we compared nodule detectability between QLD-DLIR and LD-IR. Detecting lung nodules is one of the major indications of CT, especially in the screening setting. We considered Lung-RADS category 3 or 4 nodules as positive, since those nodules alter follow-up plans in lung cancer screening programs [17]. Three thoracic radiologists showed no significant differences in sensitivity, specificity, false-positive rates, and AUFROC between QLD-DLIR and LD-IR. When nodules missed by the radiologists were reviewed (false-negative), the nodules were visualized comparably in both LD-IR and QLD-DLIR images (Figure E3), suggesting that the missing of nodules was mainly attributed to random human error rather than a different imaging technique. Noninferior nodule detection performance of QLD-DLIR over LD-IR was demonstrated in the JAFROC analysis. Jiang et al. also demonstrated the feasibility of deep learning-reconstructed ultralow-dose CT for nodule detection [14]; however, that study did not compare the performance to conventional LDCT images. Our study results suggest that radiation dose reduction up to 75% could be tried for LDCT scans conducted for the purpose of lung nodule screening. However, further validation on diverse vendors in detecting diverse abnormalities other than lung nodules should be warranted.

While the QLD-DLIR images exhibited superior results over the LD-IR images for most parameters in the quantitative image quality assessment, the radiologists assessed that LD-IR showed comparable to better image quality than QLD-DLIR for most parameters. Of particular note, the radiologists gave LD-IR better scores in overall image quality for 1-mm, sharp-kernel images. This discrepancy may primarily be due to the following two reasons. First, the radiologists were more accustomed to the texture of IR-reconstructed images and were relatively unfamiliar with DLIR-reconstructed images. In addition, the radiologists found a considerably higher level of beamhardening artifacts (3.01 vs. 3.47; P<.001), which was not assessed by the quantitative measures, and this might have affected the overall image quality assessment. Second, as DLIR was trained to reduce quantitative metrics, typically measured image noise, DLIR might have advantages in quantitative assessment. As we optimized the DLIR settings mainly for 3-mm, standard-kernel images, the 1-mm, sharp-kernel images generally yielded lower scores. Further optimization of DLIR for each image type and the addition of a beam-hardening artifact-reduction algorithm would enhance image quality and reader preferences for QLD-DLIR images.

Our study has some limitations. First, because of its retrospective nature, selection bias could have affected the comparison of image quality and lung nodule detection performance. To minimize selection bias, patients were selected consecutively. In addition, patients with six or more nodules were excluded to focus the review on nodule detection performance, which could have also yielded additional selection bias. Second, images were taken using a single CT scanner, limiting the generalizability of the study results. Third, only one deep-learning reconstruction software was tested. Fourth, the number of subsolid nodules included in this study was small (n=4), and thus meaningful subgroup analysis for subsolid nodules was limited. Further studies assessing if DLIR may properly preserve the morphology and size of the subsolid nodules would be beneficial. Fifth, the radiologists showed poor inter-reader agreement in assessing some qualitative parameters including subjective noise and presence of distortion artifacts. In addition, the radiologists gave comparable to lower scores to QLD-DLIR in assessing subjective noise while it showed lower measured noise level, possibly affected by different image textures or variable reader-familiarity to the technique. Lastly, the limit for noninferiority in nodule detection performance was set empirically rather than from preliminary analyses of nodule detection performance.

In conclusion, deep learning–reconstructed QLD images showed comparable image quality and nonin-ferior nodule detectability to standard LDCT images reconstructed with IR.

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12880-023-01081-8.

Supplementary Material 1

Acknowledgements

We sincerely thank Tae Hee Lee, MD, for his assistance in the statistical analysis of data.

Author contributions

Conceptualization: Jin Mo Goo, Ju Gang Nam Data curation: Gyeong Deok Jo, Ju Gang Nam Formal analysis: Gyeong Deok Jo, Jin Mo Goo, Ju Gang Nam Funding acquisition: Jin Mo Goo, Ju Gang Nam Investigation: Gyeong Deok Jo, Ju Gang Nam Methodology: Gyeong Deok Jo, Jin Mo Goo, Ju Gang Nam Project administration: Jin Mo Goo, Ju Gang Nam. Software: Chulkyun Ahn, Jong Hyo Kim Supervision: Jin Mo Goo, Ju Gang Nam Validation: Jin Mo Goo, Ju Gang Nam Visualization: Gyeong Deok Jo Writing-original draft: Gyeong Deok Jo, Ju Gang Nam Writing-review & editing: Gyeong Deok Jo, Jung Hee Hong, Da Som Kim, Jongsoo Park, Hyungjin Kim, Jin Mo Goo, Ju Gang Nam *Jin Mo Goo and Ju Gang Nam are co-corresponding authors. They contributed equally to this work as corresponding authors in the study conceptualization, data analysis, methodology, and draft writing/editing.

Funding

This work was supported by the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (RS-2020-KD000226, 1711174549) and the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (2022R1A2C1091805).

The funder had no role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; and in the decision to submit the article for publication.

Data Availability

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This retrospective study was approved by the Institutional Review Board of Seoul National University Hospital (IRB number: 2101-127-1190), and the requirement for informed consent was waived. This study was conducted in accordance with the Declaration of Helsinki. We followed the Strengthening the Reporting of Observational Studies in Epidemiology guideline [26]. None of the study patients have been analyzed in previous publications.

Consent for publication

Not applicable.

Competing interests

Activities related to the present article: J.H.K. is a co-CEO of ClariPi and C.A. is an employee of ClariPi. The role of these two authors (J.H.K. and C.A.) were confined to providing the deep-learning reconstruction software (ClariCT. AI), and they did not participate in data analysis or writing of original draft. Activities not related to the present article: J.G.N. received research grants from Vuno; J.M.G. received research grants from Lunit, INFINITT Healthcare, Dongkook Lifescience, and LG electronics; H.K. received consulting fees from RADISEN; holds stock and stock options in Medical IP. All other authors (G.D.J., J.H.H., D.S.K., and J.P.) declare that they have no competing interests.

Author details

¹Department of Radiology, Seoul National University Hospital and College of Medicine, Seoul 03080, Republic of Korea
 ²Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Republic of Korea
 ³ClariPi Research, Seoul 03088, Republic of Korea
 ⁴Department of Radiology, Keimyung University Dongsan Hospital, Keimyung University School of Medicine, Daegu 42601, Republic of Korea
 ⁵Department of Radiology, Busan Paik Hospital, College of Medicine, Inje University, Busan 47392, Republic of Korea
 ⁶Department of Radiology, Yeungnam University Medical Center, Yeungnam University College of Medicine, Daegu 42415, Republic of Korea

⁷Cancer Research Institute, Seoul National University, Seoul 03080, Republic of Korea

Received: 14 April 2023 / Accepted: 17 August 2023 Published online: 11 September 2023

References

- National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.
- Pastorino U, Silva M, Sestini S, Sabia F, Boeri M, Cantarutti A, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 2019;30:1162–9.
- de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized Trial. N Engl J Med. 2020;382:503–13.
- US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325:962–70.
- Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Engl J Med. 2013;368:728–36.
- Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, et al. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer. 2008;98:270–6.
- Ellmann S, Kammerer F, Allmendinger T, Hammon M, Janka R, Lell M, et al. Advanced Modeled Iterative Reconstruction (ADMIRE) facilitates radiation dose reduction in abdominal CT. Acad Radiol. 2018;25:1277–84.
- Singh S, Kalra MK, Gilman MD, Hsieh J, Pien HH, Digumarthy SR, et al. Adaptive statistical iterative reconstruction technique for radiation dose reduction in chest CT: a pilot study. Radiology. 2011;259:565–73.
- Brady SL, Trout AT, Somasundaram E, Anton CG, Li Y, Dillman JR. Improving image quality and reducing radiation dose for pediatric CT by using deep learning reconstruction. Radiology. 2021;298:180–8.
- Dadoun H, Rousseau A-L, de Kerviler E, Correas J-M, Tissier A-M, Joujou F, et al. Deep learning for the detection, localization, and characterization of focal liver lesions on abdominal US images. Radiol Artif Intell. 2022;4:e210110.
- Vaidyanathan A, van der Lubbe MFJA, Leijenaar RTH, van Hoof M, Zerka F, Miraglio B, et al. Deep learning for the fully automated segmentation of the inner ear on MRI. Sci Rep. 2021;11:2885.
- Nam JG, Ahn C, Choi H, Hong W, Park J, Kim JH, et al. Image quality of ultralow-dose chest CT using deep learning techniques: potential superiority of vendor-agnostic post-processing over vendor-specific techniques. Eur Radiol. 2021;31:5139–47.
- Greffier J, Hamard A, Pereira F, Barrau C, Pasquier H, Beregi JP, et al. Image quality and dose reduction opportunity of deep learning image reconstruction algorithm for CT: a phantom study. Eur Radiol. 2020;30:3951–9.
- Jiang B, Li N, Shi X, Zhang S, Li J, de Bock GH, et al. Deep learning reconstruction shows better lung nodule detection for ultra-low-dose chest CT. Radiology. 2022:210551.
- Kim JH, Park HS. Inventor; ClariPi Inc., assignee. Apparatus and method for ct image denoising based on deep learning. Republic of Korea patent KR20190058285A. 2019 Nov 8.

- Tatsugami F, Higaki T, Nakamura Y, Yu Z, Zhou J, Lu Y, et al. Deep learningbased image restoration algorithm for coronary CT angiography. Eur Radiol. 2019;29:5322–9.
- American College of Radiology Committee on Lung-RADS[®]. Lung-RADS Version 1.1 Assessment Categories. Available at https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads. Accessed 28 Jan 2023.
- Rubin GD, Lyo JK, Paik DS, Sherbondy AJ, Chow LC, Leung AN, et al. Pulmonary nodules on multi-detector row CT scans: performance comparison of radiologists and computer-aided detection. Radiology. 2005;234:274–83.
- Nam JG, Lee JM, Lee SM, Kang HJ, Lee ES, Hur BY, et al. High acceleration three-dimensional T1-weighted dual echo Dixon hepatobiliary phase imaging using compressed sensing-sensitivity encoding: comparison of image quality and solid lesion detectability with the standard T1-weighted sequence. Korean J Radiol. 2019;20:438–48.
- Fletcher JG, Yu L, Li Z, Manduca A, Blezek DJ, Hough DM, et al. Observer performance in the detection and classification of malignant hepatic nodules and masses with CT image-space denoising and iterative reconstruction. Radiology. 2015;276:465–78.
- Park SB. Advances in deep learning for computed tomography denoising. World J Clin Cases. 2021;9:7614–9.
- Nam JG, Hong JH, Kim DS, Oh J, Goo JM. Deep learning reconstruction for contrast-enhanced CT of the upper abdomen: similar image quality with lower radiation dose in direct comparison with iterative reconstruction. Eur Radiol. 2021;31:5533–43.
- Akagi M, Nakamura Y, Higaki T, Narita K, Honda Y, Zhou J, et al. Deep learning reconstruction improves image quality of abdominal ultra-high-resolution CT. Eur Radiol. 2019;29:6163–71.
- 24. Kim C, Kwack T, Kim W, Cha J, Yang Z, Yong HS. Accuracy of two deep learning-based reconstruction methods compared with an adaptive statistical iterative reconstruction method for solid and ground-glass nodule volumetry on low-dose and ultra-low-dose chest computed tomography: a phantom study. PLoS ONE. 2022;17:e0270122.
- Ahn CK, Heo C, Kim JH. Combined low-dose simulation and deep learning for CT denoising: application in ultra-low-dose chest CT. In: Fujita H, Lin F, Kim JH, editors. International Forum on Medical Imaging in Asia 2019. Singapore, Singapore: SPIE; 2019. p. 43.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.